openPR Logo
Press release

Global Metastatic Cancer Drug Market, Dosage, Price and Clinical Pipeline Outlook 2024

03-19-2018 08:24 AM CET | Health & Medicine

Press release from: Kuick Resarch

Global Metastatic Cancer Drug Market, Dosage, Price

Download Sample

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink: https://www.kuickresearch.com/report-global-metastatic-cancer-drug-market,-dosage,-price-and-clinical-pipeline-outlook-2024.php

Table of Contents

1. Cancer Metastasis: New Perspectives of Old Problem
1.1 Overview to Cancer
1.1.1 Process of Metastatic Cancer
1.1.2 Risk Factors Involved for the Metastasis of Cancer
1.2 Genes Involved in Metastasis of Cancer

2. Metastatic Lung Cancer
2.1 Introduction
2.2 Management Approaches for Metastatic Lung Cancer
2.3 Advancements in the Treatment of Metastatic Lung Cancer

3. Metastatic Bone Cancer
3.1 Introduction
3.2 Management Approaches of Metastatic Bone Cancer

4. Metastatic Breast Cancer
4.1 Overview
4.2 Management Methods for Metastatic Breast Cancer
4.3 Ongoing Advancements in Metastatic Breast Cancer Treatment

5. Metastatic Liver Cancer
5.1 Introduction
5.2 Management Approaches of Metastatic Liver Cancer

6. Metastatic Brain Cancer
6.1 Outline
6.2 Management Methods for Metastatic Brain Tumor
6.3 Developments in Metastatic Brain Tumors

7. Metastatic Prostate Cancer
7.1 Introduction
7.2 Management of Metastatic Prostate Cancer
7.3 Recent Advances in Metastatic Prostate Cancer Treatment

8. Process of Metastasis in Other Different Types of Cancers
8.1 Ovarian Cancer
8.2 Thyroid Cancer
8.3 Pancreatic Cancer

9. Patent, Availability, Price and Dosage Analysis of Metastatic Lung Cancer Therapeutics
9.1 Targeted Drugs
9.1.1 Erlotinib (Tarceva)
9.1.2 Gefitinib (Iressa)
9.1.3 Afatinib (Gilotrif)
9.2 Chemotherapy Drugs
9.2.1 Cisplatin
9.2.2 Topotecan (Hycamtin)
9.2.3 Pemetrexed (Alimta)

10. Patent, Availability, Price and Dosage Analysis of Metastatic Bone Cancer Therapeutics
10.1 Denosumab
10.2 Radium 223
10.3 Zoledronic acid

11. Patent, Availability, Price and Dosage Analysis of Metastatic Breast Cancer Therapeutics
11.1 Chemotherapy Drugs
11.1.1 Capecitabine
11.1.2 Eribulin (Halaven)
11.1.3 Ixabepilone (Ixempra)
11.2 Targeted Therapy Drugs
11.2.1 Avastin (Bevacizumab)
11.2.2 Herceptin

12. Patent, Availability, Price and Dosage Analysis of Metastatic Liver Cancer Therapeutics
12.1 Sorafenib (Nexavar)
12.2 Melphalan (Alkeran)

13. Patent, Availability, Price and Dosage Analysis of Metastatic Prostate Cancer Therapeutics
13.1 Taxotere (Docetaxel)
13.2 Jevtana (Cabazitaxel)
13.3 Provenge (Sipuleucel-T)

14. Market Analysis of Metastatic Cancer
14.1 Current Market Growth of Metastatic Cancer by its Types
14.2 Global Sales of Metastatic Cancers Drugs

15. Market Dynamics of Metastatic Cancer
15.1 Favorable Parameters
15.2 Challenges

16. Future Perspective of Metastatic Cancer Market

17. Global Cancer Metastases Clinical Pipeline Overview

18. Global Cancer Metastases Clinical Pipeline by Company, Indication and Phase
18.1 Research
18.2 Preclinical
18.3 Clinical
18.4 Phase-0
18.5 Phase-I
18.6 Phase-I/II
18.7 Phase-II
18.8 Phase-III
18.9 Preregistration

19. Marketed Cancer Metastases Drugs Clinical Insight
19.1 Denosumab (PRALIA, Prolia, Ranmark and Xgeva)
19.2 Radium-223 Chloride (Alpharadin and Xofigo)
19.3 Zoledronic Acid (Aclasta, Reclast and Zometa)
19.4 Pamidronic Acid (Aminomux, Aredia and Panorin)
19.5 Clodronic Acid (Ascredar, Bonefos, Bonephos, Clasteon, Clastoban, Climaclod, Clodeosten, Clodron, Clodron beta, Clody, Difosfonal, Dolkin, Hemocalcin, Lodronat, Loron, Lytos, Mebonat, Moticlod, Nikclod, Ossiten, Ostac, Osteonorm, Osteostab and Sindronat)
19.6 Ibandronic Acid (Bondronat, Boniva and Bonviva)
19.7 Thiotepa (Tepadina and Thioplex)
19.8 Miltefosine (Impavido, Miltefosin and Miltex)
19.9 Irinotecan-Eluting Beads (DEBIRI and PARAGON Bead)
19.10 Melphalan Drug Delivery System (Delcath Hepatic CHEMOSAT Delivery System for Melphalan and Melblez Kit)
19.11 Ethiodised Oil (Lipiodol)
19.12 Zoledronic Acid - Sagent Pharmaceuticals
19.13 Tc 99m Besilesomab (Scintimun)
19.14 Mopidamol (Rapenton)

20. Competitive Landscape
20.1 Allergan
20.2 Amgen
20.3 Biocompatibles International
20.4 Boehringer Ingelheim Pharma
20.5 Celsion Corporation
20.6 DexTech Medical
20.7 Immune Pharmaceuticals
20.8 GlaxoSmithKline
20.9 Hospira
20.10 Insmed
20.11 Novartis
20.12 Pfizer
20.13 Roche

Figure 1-1: Reasons for the Development of Cancer Cases (%)
Figure 1-2: Process Involved in the Metastasis of Cancer
Figure 1-3: Classes of Genes Participating in Metastatic Process in Cancer
Figure 2-1: Diagnostic Methods for Metastatic Lung Cancer
Figure 3-1: Diagnostic Approaches for Metastatic Bone Cancer
Figure 4-1: Metastatic Breast Cancer Diagnostic Methods
Figure 5-1: Metastatic Liver Cancer Diagnostic Methods
Figure 5-2: Treatment Approaches for Metastatic Liver Cancer
Figure 6-1: Diagnostic Approaches to Brain Tumor
Figure 6-2: Treatment Methods for Metastatic Brain Tumor
Figure 7-1: Diagnostic Approaches for Metastatic Prostate Cancer
Figure 7-2: Treatment Methods for Metastatic Prostate Cancer
Figure 9-1: Tarceva andndash; Patent Approval and Expiration Year for Advance Stage Lung Cancer
Figure 9-2: Tarceva andndash; Available Concentrations (mg), 2018
Figure 9-3: Tarceva andndash; Dosage Analysis and Dose Modifications (mg/Day), 2018
Figure 9-4: Tarceva andndash; Increased Dosage by Condition (mg/Day), 2018
Figure 9-5: Tarceva andndash; Price Analysis by Concentration (US$), 2018
Figure 9-6: Tarceva andndash; Therapy Cost Analysis (US$/Patient), 2018
Figure 9-7: Gefitinib andndash; Drug Patent Approval Year and Expiration Year for Lung Cancer
Figure 9-8: Gefitinib andndash; Clinical Efficacy by Patients Undergoing Treatment (%), 2018
Figure 9-9: Gefitinib andndash; Dosage Analysis (mg), 2018
Figure 9-10: Gefitinib andndash; Available Concentrations (mg), 2018
Figure 9-11: Gefitinib andndash; Therapy Cost Analysis (US$/Patient), 2018
Figure 9-12: Afatinib andndash; Patent Approval and Expiration Year for the Treatment of Lung Cancer
Figure 9-13: Afatinib - Available Concentrations (mg), 2018
Figure 9-14: Afatinib andndash; Therapy Cost Analysis (US$), 2018
Figure 9-15 Cisplatin andndash; Available Concentrations (ml), 2018
Figure 9-16: Cisplatin andndash; Price Analysis by Concentration (US$), 2018
Figure 9-17: Topotecan - Patent Approval and Expiration Year
Figure 9-18: Topotecan andndash; Available Concentration by Form (mg), 2018
Figure 9-19: Topotecan andndash; Dosage Analysis by Route of Administration (mg/m2/Dose), 2018
Figure 9-20: Topotecan andndash; Treatment Cycle Analysis (Number of Days), 2018
Figure 9-21: Topotecan andndash; Dosage Analysis by Route of Administration (mg/Cycle), 2018
Figure 9-22: Topotecan andndash; Capsule Price Analysis by Concentration (US$/Unit), 2018
Figure 9-23: Topotecan andndash; Price Analysis by Drug Form (US$/Packet), 2018
Figure 9-24: Alimta Patent Approval and Expiration Year for Advanced Lung Cancer Treatment
Figure 9-25: Alimta - Available Concentration (mg), 2018
Figure 9-26: Alimta andndash; Dosage Analysis (mg/Day), 2018
Figure 9-27: Alimta andndash; Price Analysis by Concentration (US$), 2018
Figure 10-1: Patent Approval and Expiry Year of Denosumab Drug
Figure 10-2: Denosumab - Available Concentration and Dosage Analysis by Brand (mg/Day), 2018
Figure 10-3: Denosumab Comparative Cost Analysis andndash; Xgeva v/s Prolia (US$/Unit)
Figure 10-4: Xofigo Patent Approval and Expiry Year
Figure 10-5: Xofigo andndash; Therapy Cost Analysis (US$), 2018
Figure 10-6: Patent Approval Year and Expiry Year
Figure 10-7: Zometa andndash; Available Concentrations (mg/ml), 2018
Figure 10-8: Zometa - Dosage and Treatment Cycle Duration Analysis (mg/Cycle), 2018
Figure 10-9: Zometa andndash; Price Analysis (US$/Vial), 2018
Figure 11-1: Capecitabine - Available Concentrations (mg), 2018
Figure 11-2: Capecitabine andndash; Dosage Analysis (mg/m2/Day), 2018
Figure 11-3: Capecitabine andndash; Treatment Cycle Duration Analysis (Number of Weeks), 2018
Figure 11-4: Capecitabine and Xeloda - Comparative Cost Analysis by Concentration (US$/Packet), 2018
Figure 11-5: Eribulin Drug Patent Approval Year and Expiration Year for Metastatic Breast Cancer
Figure 11-6: Eribulin andndash; Availability and Dosage Analysis (mg), 2018
Figure 11-7: Eribulin andndash; Price Analysis (US$), 2018
Figure 11-8: Eribulin andndash; Clinical Efficacy Based on Clinical Trial Results (%), 2018
Figure 11-9: Ixabepilone Patent Approval and Expiry Year for Breast Cancer Treatment
Figure 11-10: Ixempra - Available Concentrations (MG), 2018
Figure 11-11: Ixempra andndash; Dosage Analysis (mg/m2/Day), 2018
Figure 11-12: Ixempra andndash; Price Analysis by Concentration (US$), 2018
Figure 11-13: Avastin Patent Approval and Expiration Year
Figure 11-14: Avastin andndash; Available Concentrations (ml), 2018
Figure 11-15: Avastin andndash; Average Dosage Analysis (mg/kg), 2018
Figure 11-16: Avastin andndash; Price Analysis (US$), 2018
Figure 11-17: Avastin andndash; Clinical Efficacy Based on Clinical Trial Results (%), 2018
Figure 11-18: Herceptin - Available Concentrations (mg), 2018
Figure 11-19: Herceptin andndash; Dosage Analysis (mg/kg), 2018
Figure 11-20: Herceptin andndash; Price Analysis by Concentration (US$), 2018
Figure 12-1: Nexavar - Patent Approval and Expiry Year
Figure 12-2: Nexavar andndash; Availability and Dosage Analysis (mg), 2018
Figure 12-3: Nexavar - Price Analysis (US$), 2018
Figure 12-4: Nexavar andndash; Therapy Cost Analysis (US$/Patient), 2018
Figure 12-5: Alkeran - Drug Patent Approval and Expiration Year
Figure 12-6: Alkeran andndash; Available Concentrations by Drug Form (mg), 2018
Figure 12-7: Alkeran andndash; Treatment Cycle Analysis (By Number), 2018
Figure 12-8: Alkeran andndash; Price Analysis by Drug Form (US$), 2018
Figure 13-1: Docetaxel - Available Concentrations (mg/ml), 2018
Figure 13-2: Docetaxel andndash; Dosage Analysis (mg/m2/Dose), 2018
Figure 13-3: Docetaxel andndash; Price Analysis (US$/Unit), 2018
Figure 13-4: Jevtana - Patent Approval and Expiry Year for Metastatic Prostate Cancer Treatment
Figure 13-5: Jevtana andndash; Available Concentration and Dosage Analysis (mg), 2018
Figure 13-6: Jevtana andndash; Price Analysis (US$), 2018
Figure 13-7: Patent Approval Years of Provenge Drug in US and Europe
Figure 13-8: Provenge andndash; Number of Autologous CD54+ Activated Cells (Million)
Figure 13-9: Provenge andndash; Dosage Administration (Minutes)
Figure 13-10: Provenge - Average Duration of Therapy
Figure 13-11: Provenge - Cost of Intravenous Solution and per Unit Cost, US$
Figure 13-12: Provenge - Therapy Cost Analysis (US$/Infusion), 2018
Figure 13-13: Provenge andndash; Average Cost (US$/Patient), 2018
Figure 13-14: Provenge andndash; Therapy Cost Analysis (US$/Treatment Course), 2018
Figure 13-15: Overall Survival Rate among the Patients Using Provenge Drug (%)
Figure 14-1: Global andndash; Metastatic Cancer Therapy Market Forecast (US$ Billion), 2017-2027
Figure 14-2: Global andndash; Breast Cancer Therapeutics Forecast (US$ Billion), 2016-2026
Figure 14-3: Global - Prostate Cancer Therapeutics Market Forecast (US$ Billion), 2016-2027
Figure 14-4: Global andndash; Tarceva Sales (US$ Million), 2015 andndash; 2017
Figure 14-5: Global andndash; Iressa Sales Analysis (US$ Million), 2015 - 2017
Figure 14-6: Global - Hycamtin Sales Analysis (US$ Million), 2015 and 2016
Figure 14-7: Global - Alimta Sales Analysis (US$ Million), 2015 andndash; 2017*
Figure 14-8: Global - Prolia Sales Analysis (US$ Million), 2015 andndash; 2017*
Figure 14-9: Global - Xofigo Sales Analysis (US$ Million), 2015 and 2017*
Figure 14-10: Global - Eribulin Sales Analysis (US$ Million), 2015 and 2016
Figure 14-11: Global - Avastin Sales Analysis (US$ Billion), 2015 andndash; 2017*
Figure 14-12: Global andndash; Herceptin Sales Analysis (US$ Billion), 2015 andndash; 2017*
Figure 14-13: Global - Nexavar Sales Analysis (US$ Million), 2015 andndash; 2017*
Figure 14-14: Global - Jevtana Sales Analysis (US$ Million), 2015 andndash; 2017*
Figure 14-15: Global - Provenge Sales Analysis (US$ Million), 2015 and 2016
Figure 15-1: Favorable Parameters to Metastatic Cancer Market Growth
Figure 15-2: Challenges for the Development of Metastatic Cancer Treatment
Figure 17-1: Global Cancer Metastases Pipeline by Phase (%), 2018 till 2024
Figure 17-2: Global Cancer Metastases Pipeline by Phase (Number), 2018 till 2024
Figure 17-3: Global Cancer Metastases Pipeline by Phase (%), 2018 till 2024
Figure 17-4: Global Cancer Metastases Pipeline by Phase (Number), 2018 till 2024






Table 3-1: Role of Tumor Secreted Factors in Establishment of Osteolytic and Osteoblastic Metastasis
Table 4-1: Organ Specific Breast Cancer Metastasis Progression and Virulence
Table 6-1: Modern Challenges and Solutions in Management of Brain Metastasis
Table 9-1: Patients Benefited by Using Afatinib Drug for Metastatic Lung Cancer
Table 9-2: Formulation and Preparation of Topotecan Drug, mg
Table 11-1: Clinical Efficacy of Using Eribulin for Metastatic Breast Cancer Treatment
Table 11-2: Clinical Efficacy of Using Ixempra for Metastatic Breast Cancer Treatment
Table 11-3: Clinical Efficacy Result of Avastin Drug with Paclitaxel drug
Table 11-4: Clinical Efficacy for the use of Herceptin Combined with Paclitaxel or Docetaxel

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Metastatic Cancer Drug Market, Dosage, Price and Clinical Pipeline Outlook 2024 here

News-ID: 982760 • Views:

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Figure

Floralite - Reduce Fat & Get Attractive Figure How To Buy!
Floralite Have you been working on your eating routine without seeing the results that you are anticipating? There is indeed thing called Floralite diet pills. Advantages of Floralite Floralite One of various things to esteem about this thing is that it's made expressly for the Floralite diet. That is an epic notwithstanding considering the way that when you use a thing that is custom fitted to work with the movements
THE WORLD'S MOST CONTROVERSIAL ACTION FIGURE...EVER!
FOR IMMEDIATE RELEASE THE WORLD'S MOST CONTROVERSIAL ACTION FIGURE...EVER! Contact: William Hirsch - Schlock Toys @ +1-949-677-9353 or DocSchlock@SchlockToys.com Featured on Tomi with Fox News host Tomi Lahren! SCHLOCK TOYS join forces with Kickstarter to Make Toys Great Again! The Kickstarter campaign page can be found HERE: https://www.kickstarter.com/projects/schlocktoys/collectors-edition-talking-trump-2020-man-of-action-figure/description “What a great message to be sent, and I think Trump himself would love this and that he’d be excited about it!” - Tomi Lahren, Fox News “You
Macarons Market Latest Sales Figure Signals More Opportunities Ahead
Global Macarons Sales Market(Sales,Revenue and competitors Analysis of Major Market)from 2014-2026 is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the Global Macarons Market. Some of the key players profiled in the study are La Dure,
Global Womens Figure Skates Market Growth 2019-2024
LP INFORMATION offers a latest published report on Womens Figure Skates Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. According to this study, over the next five years the Womens Figure Skates market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019.
Figure Skating Equipment Market Report 2018: Segmentation by Type (Figure Skate …
Global Figure Skating Equipment market research report provides company profile for SP-Teri, Graf Skate, Riedell Shoes, Roces, American Athletic, Rollerblade, Winnwell, Dongguan King Line, Jackson Ultima, HD Sports(MK Blades, John Wilson), Edea, Risport Skates, Paramount Skates and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY
Long-lasting Performance Improvement with Key Figure Analysis
Vienna/Reutlingen, October 17, 2012 – Manz, a leading high-tech mechanical engineering company, is optimizing its processes in strategic sourcing in order to recognize the risks and potential associated with each supplier early on so that the sourcing department can react to them in time. POOL4TOOL’s customized eSolutions localize and analyze key figures that are relevant to the decision making process, and displays these figures in a comprehensive and transparent way.